AltPep
Develops early disease-modifying treatments and detection tools for amyloid diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
* | $52.9m | Series B | |
| Total Funding | 000k | ||
Related Content
AltPep is a privately-held biotech startup that operates in the healthcare sector, specifically focusing on the development of early disease-modifying treatments and detection tools for amyloid diseases such as Alzheimer's and Parkinson's. The company's primary objective is to identify these diseases long before symptoms occur and neutralize the toxic soluble oligomers associated with them.
AltPep's business model revolves around the development and commercialization of its proprietary platform based on a library of custom-designed synthetic peptides. This library is used to target one of the earliest molecular triggers of amyloid diseases. The company is also developing highly sensitive blood tests to aid in the early detection of these diseases.
The company recently raised $52.9 million in venture financing, indicating strong investor confidence in its innovative approach. The funds will be used to advance its novel therapeutics into the clinical stage, which is a critical step towards commercialization.
AltPep's clients are primarily healthcare providers and patients suffering from amyloid diseases. The company generates revenue through the development and sale of its diagnostic tools and therapeutic treatments.
In summary, AltPep is a promising biotech startup with a unique approach to tackling some of the most challenging diseases in healthcare. Its innovative platform and strong financial backing position it well for future growth in the biotech industry.
Keywords: Biotech, Startup, Healthcare, Alzheimer's, Parkinson's, Amyloid Diseases, Synthetic Peptides, Disease Detection, Disease Treatment, Venture Financing.